Nautilus Biotechnology added Baylor College of Medicine as the first customer in its Voyager early access program, enabling Baylor investigators to test the platform’s single‑molecule proteomics capabilities for tumor proteoform profiling. The Voyager combines dense nano‑array flow cells, imaging and machine learning to map intact proteins and proteoforms at scale; Nautilus is rolling out assays beginning with tau proteoforms. Technical clarification: single‑molecule proteomics aims to measure intact protein isoforms and post‑translational modifications that conventional shotgun mass spectrometry can miss, potentially improving biomarker discovery and translational oncology studies.